Evaluation of outpatient treatment for non-hospitalised patients with COVID-19: The experience of a regional centre in the UK
Goodwin et al.
, Evaluation of outpatient treatment for non-hospitalised patients with COVID-19: The experience of a regional..
, PLOS ONE, doi:10.1371/journal.pone.0281915
Retrospective 604 outpatients in the UK, showing lower risk of hospitalization with molnupiravir treatment, without statistical significance due to the small number of hospitalizations.Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer [Hadj Hassine, Swanstrom]. See [Fountain-Jones, Sanderson, ] for analysis of variants potentially created by molnupiravir.
risk of death, 110.0% higher, RR 2.10, p = 0.47, treatment 1 of 80 (1.2%), control 2 of 336 (0.6%).
risk of hospitalization, 58.0% lower, RR 0.42, p = 0.70, treatment 1 of 80 (1.2%), control 10 of 336 (3.0%), NNT 58, COVID-19 related.
risk of hospitalization, 53.3% lower, RR 0.47, p = 0.39, treatment 2 of 80 (2.5%), control 18 of 336 (5.4%), NNT 35, all cause.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Goodwin et al., 15 Mar 2023, retrospective, United Kingdom, peer-reviewed, 3 authors, study period 22 December, 2021 - 20 February, 2022.
Abstract: PLOS ONE
Evaluation of outpatient treatment for nonhospitalised patients with COVID-19: The
experience of a regional centre in the UK
Amanda T. Goodwin ID1*, Jonathan S. Thompson2, Ian P. Hall1
1 NIHR Nottingham Biomedical Research Centre & University of Nottingham, Nottingham, United Kingdom,
2 Department of Infectious Diseases, Nottingham University Hospitals, Nottingham, United Kingdom
Citation: Goodwin AT, Thompson JS, Hall IP
(2023) Evaluation of outpatient treatment for nonhospitalised patients with COVID-19: The
experience of a regional centre in the UK. PLoS
ONE 18(3): e0281915. https://doi.org/10.1371/
Editor: Seung-Hwa Lee, Samsung Medical Center,
REPUBLIC OF KOREA
Received: July 18, 2022
Accepted: February 5, 2023
Published: March 15, 2023
Peer Review History: PLOS recognizes the
benefits of transparency in the peer review
process; therefore, we enable the publication of
all of the content of peer review and author
responses alongside final, published articles. The
editorial history of this article is available here:
Copyright: © 2023 Goodwin et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.